Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about the importance of treating underlying sleep disorders in patients with seizures, especially within a value-based care (VBC) model.
Poor sleep usually worsens seizures, says Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital.
Transcript
What role does value-based care play in patients with epilepsy who have sleep disorders?
When it comes to value-based care, it really depends on how the measurement is done. Whether we are talking about value in the immediate setting, or value in the longer-term health of the patient. I would say the treatment of sleep disorders is important, both in the short-term and in the long-term setting. In terms of the short-term setting, poor sleep is now a very well recognized risk factor for car accidents. So, from that perspective, it's a big risk, although I'm not sure how well this is actually reflected into the models of pay for services. But in terms of the overall health, there is currently a massive amount of evidence that various sleep disorders tend to be culprits for worsening health, and what I'll be talking about is going to be the role of sleep apnea for patients with epilepsy. Sleep apnea specifically is a well-recognized risk factor for myocardial infarction. It's a risk factor for stroke, as you know, stroke leads to disability and a lot of health utilization. Various sleep disorders have been implicated in the pathogenesis of worsening of various disorders of cognition, they have a role in dementia, they have a role in mood disorders, and also epilepsy, and I'm going to be talking about this a little bit more in detail because poor sleep tends to worsen seizures, that's the bottom line. So, in a value-based model, the frequency of seizures should be balanced with treatment of any underlying sleep disorders.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More